Drug-Drug Interaction Study of ABP-671 in Gout Patients

Part of paid clinical trials in Cary, North Carolina.

Sponsor
Atom Therapeutics Co., Ltd
Study ID
NCT07367971
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • DDI (Drug-Drug Interaction)
  • Gout
  • Gout Chronic

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ABP-671 plus allopurinol — DRUG
    All subjects undergo three sequential 7-day periods: Period 1 (Day 1-7): Allopurinol； Period 2 (Day 1-7): Allopurinol Plus ABP-671； Period 3 (Day 1-7): ABP-671；

Study Details

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Key Dates

Start date
Jan 23, 2026
Status verified
Apr 2026
Primary completion
Jul 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ABP-671

Primary Outcome Measure

Maximum plasma concentration (Cmax) of allopurinol [ Time Frame: Base line, through Day1, Day 7,Day8,D14,D15,D21 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Wakefield Clinical ResearchCaryNorth Carolina27560
Xiaohuan Li, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cary, NC

By research site
Wakefield Clinical Research· Cary, NC

Related Studies